journal
MENU ▼
Read by QxMD icon Read
search

Rheumatology and Therapy

journal
https://www.readbyqxmd.com/read/28936808/impact-of-tocilizumab-monotherapy-on-clinical-and-patient-reported-quality-of-life-outcomes-in-patients-with-rheumatoid-arthritis
#1
Leslie R Harrold, Ani John, George W Reed, Tmirah Haselkorn, Chitra Karki, YouFu Li, Jennie Best, Steve Zlotnick, Joel M Kremer, Jeffrey D Greenberg
INTRODUCTION: Tocilizumab (TCZ) monotherapy has been proven as an effective treatment for rheumatoid arthritis (RA) in clinical trials. However, there are limited data available regarding the effectiveness of TCZ monotherapy in real-world clinical settings in the United States. The objective of this study was to evaluate the impact of TCZ monotherapy on disease activity and patient-reported outcomes (PROs) in a US-based observational cohort of patients with RA seen in routine clinical practice...
September 21, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28900875/single-arm-study-of-etanercept-in-adult-patients-with-moderate-to-severe-rheumatoid-arthritis-who-failed-adalimumab-treatment
#2
Louis Bessette, Majed Khraishi, Alan J Kivitz, Arunan Kaliyaperumal, Rama Grantab, Melanie Poulin-Costello, Maya Isaila, David Collier
INTRODUCTION: To evaluate the efficacy and safety of etanercept treatment in adult patients with moderate to severe rheumatoid arthritis (RA) who failed to respond (primary failure) or lost a satisfactory response (secondary failure) to adalimumab. METHODS: All patients discontinued prior adalimumab treatment and continued methotrexate with etanercept 50 mg once weekly for 24 weeks. The primary study endpoint was American College of Rheumatology 20% improvement criteria (ACR20) at week 12...
September 12, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28849401/a-review-of-the-use-of-secukinumab-for-psoriatic-arthritis
#3
REVIEW
Nupur U Patel, Nora C Vera, Emily Rose Shealy, Margaret Wetzel, Steven R Feldman
Psoriatic arthritis (PsA) is a chronic, seronegative spondyloarthropathy associated with psoriasis (PsO). Treatment options range from non-pharmacologic measures to NSAIDS, DMARDs, and biologics, depending on patient presentation. Secukinumab (Cosentyx©) is a new biologic treatment option that was approved for use in treating adult patients with PsA in October 2016. Our paper explores the clinical trial evidence available for secukinumab to examine its safety and efficacy as a therapeutic agent for the treatment of PsA...
August 28, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28840531/long-term-effectiveness-of-adalimumab-in-patients-with-rheumatoid-arthritis-an-observational-analysis-from-the-corrona-rheumatoid-arthritis-registry
#4
Dimitrios A Pappas, Joel M Kremer, Jenny Griffith, George Reed, Bob Salim, Chitra Karki, Vishvas Garg
INTRODUCTION: Current recommendations for the management of rheumatoid arthritis (RA) focus on a treat-to-target approach with the objective of maximizing long-term health-related quality-of-life in patients with RA. Published studies from randomized clinical trials have reported limited data regarding the long-term efficacy and safety of adalimumab in patients with RA. This study aims to evaluate the long-term (10+ years) persistency and effectiveness of adalimumab in patients with RA in a real-world setting...
August 24, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28831751/discontinuation-of-biologic-therapy-in-rheumatoid-arthritis-analysis-from-the-corrona-ra-registry
#5
Vibeke Strand, Paul Miller, Setareh A Williams, Katherine Saunders, Shannon Grant, Joel Kremer
INTRODUCTION: Despite the availability of multiple effective therapies, discontinuation/switching of treatment is common for many patients with rheumatoid arthritis (RA). This study was designed to examine initiation of biologic disease-modifying anti-rheumatic drugs (bDMARDs) within the Consortium of Rheumatology Researchers of North America (Corrona) RA Registry, and characterize reasons for discontinuation. METHODS: Inclusion criteria were: Corrona-registered adults (≥18 years) with RA (2002-2011); age of RA onset: ≥16 years; ≥6 months' follow-up after initiation of first/subsequent bDMARD...
August 22, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28831712/treatment-with-biologicals-in-rheumatoid-arthritis-an-overview
#6
REVIEW
Philipp Rein, Ruediger B Mueller
Management and therapy of rheumatoid arthritis (RA) has been revolutionized by the development and approval of the first biological disease-modifying antirheumatic drugs (bDMARDs) targeting tumor necrosis factor (TNF) α at the end of the last century. Today, numerous efficacious agents with different modes of action are available and achievement of clinical remission or, at least, low disease activity is the target of therapy. Early therapeutic interventions aiming at a defined goal of therapy (treat to target) are supposed to halt inflammation, improving symptoms and signs, and preserving structural integrity of the joints in RA...
August 22, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28819927/switching-from-immediate-release-to-delayed-release-prednisone-in-moderate-to-severe-rheumatoid-arthritis-a-practice-based-clinical-study
#7
Ara H Dikranian, Rubaiya Mallay, Mike Marshall, Megan Francis-Sedlak, Robert J Holt
INTRODUCTION: Rheumatoid arthritis (RA) produces debilitating morning stiffness. Exogenous glucocorticoids can help with these symptoms when timed appropriately. Bedtime dosing of delayed-release prednisone (DR-prednisone) matches the rise of inflammatory cytokines before awakening and can improve stiffness and other RA symptoms. A prospective open-label study was conducted in patients currently on stable doses of immediate-release prednisone (IR-prednisone) who were switched to DR-prednisone to analyze the incremental benefit of better timed and lower dose glucocorticoid therapy...
August 17, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28815445/identification-and-treatment-optimization-of-comorbid-depression-in-rheumatoid-arthritis
#8
Mellissa H Withers, Louella T Gonzalez, George A Karpouzas
Patients with rheumatoid arthritis (RA) suffer from high rates of depression but depression often remains undiagnosed and untreated among RA patients. Because of its high prevalence and its profound impact on functional disability and health-related quality of life, prompt recognition and management of comorbid depression is urgently needed in patients with RA. Rheumatologists face the challenge of addressing depression in their clinical interactions with patients. The purpose of this paper is to present the prevalence of comorbid depression in RA, to delineate the consequences of depression among RA patients, to discuss the barriers to the identification of depression among RA patients, and to outline a set of recommendations to identify and treat comorbid depression that could be implemented within the rheumatology clinic setting...
August 16, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28808949/practical-management-of-respiratory-comorbidities-in-patients-with-rheumatoid-arthritis
#9
REVIEW
James Bluett, Meghna Jani, Deborah P M Symmons
Lung disease is one of the most common causes of extra-articular morbidity and mortality in patients with rheumatoid arthritis (RA). Development of pulmonary manifestations may be due to the systemic disease itself; to serious respiratory adverse events such as pneumonitis and infections secondary to therapy; or to lifestyle habits such as smoking. Rheumatologists often need to make important treatment decisions and plan future care in RA patients with respiratory comorbidities, despite the absence of clear evidence or consensus...
August 14, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28791611/chronic-autoimmune-epithelitis-in-sj%C3%A3-gren-s-syndrome-and-primary-biliary-cholangitis-a-comprehensive-review
#10
REVIEW
Carlo Selmi, M Eric Gershwin
Within the spectrum of autoimmune diseases, Sjögren's syndrome and primary biliary cholangitis are exemplary and can be coined as chronic epithelitis based on their frequent coexistence in clinical practice and the highly specific immune-mediated injury of the small bile ducts and the exocrine glands. The pathogenic mechanisms underlying the diseases are similar, with apoptosis being the key element leading to organ-specific immune-mediated injury directed against the small bile ducts and salivary gland epithelia, respectively along with similar epidemiological features, such as female predominance and the age of onset in the fifth decade of life...
August 8, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28762213/comparative-effectiveness-of-adalimumab-versus-secukinumab-for-the-treatment-of-psoriatic-arthritis-a-matching-adjusted-indirect-comparison
#11
Vibeke Strand, Keith A Betts, Manish Mittal, Jinlin Song, Martha Skup, Avani Joshi
INTRODUCTION: The Phase III FUTURE I and II trials demonstrated the clinical efficacy of secukinumab in active psoriatic arthritis (PsA). In the absence of head-to-head trials, this study compared the clinical efficacy and cost effectiveness of adalimumab 40 mg versus secukinumab 150 and 300 mg for the treatment of active PsA. METHODS: A matching-adjusted indirect comparison was conducted using individual patient data from the ADEPT trial of adalimumab and published data from FUTURE I and II...
July 31, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28755063/brazilian-experience-of-the-treatment-of-alopecia-universalis-with-the-novel-antirheumatic-therapy-tofacitinib-a-case-series
#12
Morton Scheinberg, Regina Adalva de Lucena Couto Océa, Boris Afonso Cruz, Sineida Berbert Ferreira
INTRODUCTION: Alopecia universalis is an autoimmune disorder for which there is no known effective therapy. Tofacitinib-a novel antirheumatic therapy for rheumatoid arthritis-has been shown in some reports to induce sustained hair growth in patients with alopecia universalis. CASE SERIES: Here, we review the experiences of four different rheumatologists across the country regarding four Brazilian patients with alopecia universalis who were treated with tofacitinib ...
July 28, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28752316/practical-management-of-cardiovascular-comorbidities-in-rheumatoid-arthritis
#13
REVIEW
Roberta Gualtierotti, Nicola Ughi, Giovanni Marfia, Francesca Ingegnoli
Cardiovascular (CV) comorbidities are a frequent extra-articular manifestation of rheumatoid arthritis (RA). Cardiovascular disease (CVD) with accelerated atherosclerosis is a major cause of morbidity and mortality in patients with RA. Subclinical CVD may be present since the early phase of RA. Not only traditional but also non-traditional CV risk factors are involved in the pathogenesis of RA-related CVD. Due to the lack of specifically designed randomized clinical trials, it is still unclear which tools to use to perform CV risk assessment, how to interpret the results and which interventions are appropriate in RA patients both to prevent and to manage CVD...
July 27, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28685293/the-effect-size-of-fibromyalgia-on-pg-vas-in-rheumatoid-arthritis-patients-adjustment-proposal-in-das28-esr-letter-to-the-editor-regarding-challa-d-n-v-crowson-c-s-davis-j-m-rheumatol-ther-2017-4-201-doi-10-1007-s40744-017-0063-5
#14
LETTER
David Vega-Morales, Luis Ivan Lozano-Plata, Jorge Antonio Esquivel-Valerio
No abstract text is available yet for this article.
July 6, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28600789/improving-the-management-of-psoriatic-arthritis-and-axial-spondyloarthritis-roundtable-discussions-with-healthcare-professionals-and-patients
#15
REVIEW
Marco Garrido-Cumbrera, Ottfrid Hillmann, Raj Mahapatra, David Trigos, Petra Zajc, Luisa Weiss, Galya Bostynets, Laure Gossec, Laura C Coates
Psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) are both chronic, inflammatory conditions that result in a substantial burden of disease and reduced quality of life for patients. Patient involvement in developing optimal disease management strategies, including defining appropriate goals, therapies, and treatment options, as well as in setting policy priorities and agendas, is key. A working group of patient organization representatives and rheumatologists explored what patients consider to be unmet needs, important treatment gaps, and future priorities in PsA and AxSpA management...
June 9, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28488206/the-patient-global-assessment-of-disease-activity-in-rheumatoid-arthritis-identification-of-underlying-latent-factors
#16
Divya N V Challa, Cynthia S Crowson, John M Davis
INTRODUCTION: The patient global assessment of disease activity is a crucial component of various measures of disease activity in rheumatoid arthritis (RA). Our objective was to identify underlying latent traits driving the patient global assessment using a quantitative, multivariable data reduction approach. METHODS: This was a prospective cross-sectional study of consecutive patients with RA. The patient sample was stratified to include 50 patients with patient-provider discordance (i...
June 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28474206/erratum-to-impact-of-participation-in-the-adalimumab-humira-patient-support-program-on-rheumatoid-arthritis-treatment-course-results-from-the-passion-study
#17
Filip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, Naijun Chen, Chen Wang, Vishvas Garg, Jasmina Kalabic
No abstract text is available yet for this article.
June 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28364382/hypersensitivity-to-orthopedic-implants-a-review-of-the-literature
#18
REVIEW
Joseph Wawrzynski, Joseph A Gil, Avi D Goodman, Gregory R Waryasz
Awareness of rare etiologies for implant failure is becoming increasingly important. In addition to the overall increase in joint arthroplasties, revision surgeries are projected to increase dramatically in the coming years, with volume increasing up to seven-fold between 2005 and 2030. The literature regarding the relationship between metal allergy and implant failure is controversial. It has proven difficult to determine whether sensitization is a cause or a consequence of implant failure. Testing patients with functional implants is not a clinically useful approach, as the rate of hypersensitivity is higher in implant recipients than in the general population, regardless of the status of the implant...
June 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28364381/adalimumab-with-methotrexate-in-treatment-na%C3%A3-ve-japanese-patients-with-rheumatoid-arthritis-at-risk-of-progressive-structural-joint-damage-a-postmarketing-observational-study
#19
Yukiko Ito, Kaori Hozumi, Yukiko Okada, Sarina Kurimoto
INTRODUCTION: The objective of this study was to evaluate the real-world safety and effectiveness of adalimumab with methotrexate (MTX) in disease-modifying antirheumatic drug (DMARD)- and biologic-naïve Japanese patients with rheumatoid arthritis (RA) at risk of progressive structural joint damage. METHODS: This multicenter, prospective, observational, postmarketing surveillance study was conducted between February 2013 and April 2015 at 84 centers in Japan. Patients with RA at risk of progressive structural joint damage were enrolled and initiated treatment with adalimumab and MTX...
June 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28361468/impact-of-participation-in-the-adalimumab-humira-patient-support-program-on-rheumatoid-arthritis-treatment-course-results-from-the-passion-study
#20
Filip Van den Bosch, Andrew J K Ostor, Siegfried Wassenberg, Naijun Chen, Chen Wang, Vishvas Garg, Jasmina Kalabic
INTRODUCTION: Patients with rheumatoid arthritis (RA) who are treated with adalimumab (ADA) are offered a proprietary patient support program (PSP, AbbVie Care(®)). The main objective of this study was to examine the effectiveness of ADA on RA treatment course over time in the context of PSP utilization. METHODS: PASSION was a 78-week post-marketing observational study of RA patients with an insufficient response to ≥1 DMARD newly initiating ADA in routine clinical care that was conducted in Europe, Israel, Mexico, Puerto Rico, and Australia...
June 2017: Rheumatology and Therapy
journal
journal
53766
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"